Functionalization of Morin-Loaded PLGA Nanoparticles with Phenylalanine Dipeptide Targeting the Brain.
Mario Alonso-GonzálezEmilia BarciaJuan-Francisco GonzálezConsuelo MontejoLuis García-GarcíaMonica-Carolina Villa-HermosillaSofia NegroAna-Isabel Fraguas-SánchezAna Fernández-CarballidoPublished in: Pharmaceutics (2022)
Alzheimer's disease (AD) is the most prevalent neurodegenerative disorder, with its incidence constantly increasing. To date, there is no cure for the disease, with a need for new and effective treatments. Morin hydrate (MH) is a naturally occurring flavonoid of the Moraceae family with antioxidant and anti-inflammatory properties; however, the blood-brain barrier (BBB) prevents this flavonoid from reaching the CNS when aiming to potentially treat AD. Seeking to use the LAT-1 transporter present in the BBB, a nanoparticle (NPs) formulation loaded with MH and functionalized with phenylalanine-phenylalanine dipeptide was developed (NPphe-MH) and compared to non-functionalized NPs (NP-MH). In addition, two formulations were prepared using rhodamine B (Rh-B) as a fluorescent dye (NPphe-Rh and NP-Rh) to study their biodistribution and ability to cross the BBB. Functionalization of PLGA NPs resulted in high encapsulation efficiencies for both MH and Rh-B. Studies conducted in Wistar rats showed that the presence of phenylalanine dipeptide in the NPs modified their biodistribution profiles, making them more attractive for both liver and lungs, whereas non-functionalized NPs were predominantly distributed to the spleen. Formulation NPphe-Rh remained in the brain for at least 2 h after administration.
Keyphrases
- drug delivery
- blood brain barrier
- quantum dots
- cancer therapy
- anti inflammatory
- oxide nanoparticles
- drug release
- cerebral ischemia
- white matter
- resting state
- molecularly imprinted
- pet imaging
- risk factors
- cognitive decline
- computed tomography
- living cells
- african american
- brain injury
- subarachnoid hemorrhage
- highly efficient
- mild cognitive impairment